Massimo Costanza

Dr. Massimo Costanza


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Autoimmunity Reviews
Verified
Journal Article
Closed access
MCMassimo Costanza
Massimo Costanza
NBNadine Binart
Nadine Binart
LSLawrence Steinman
Lawrence Steinman
RPRosetta Pedotti
Rosetta Pedotti

1 April 2011 in Laboratory Investigation
Verified
Journal Article
Closed access
SPSilvia Piconese
Silvia Piconese
MCMassimo Costanza
Massimo Costanza
SMSilvia Musio
Silvia Musio
CTClaudio Tripodo
Claudio Tripodo
Pietro Luigi PolianiPietro Luigi Poliani
Pietro Luigi Poliani
RPRosetta Pedotti
Rosetta Pedotti

1 June 2015 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
MAMhamad Abou-Hamdan
Mhamad Abou-Hamdan
MCMassimo Costanza
Massimo Costanza
EFElena Fontana
Elena Fontana
MDMarco Di Dario
Marco Di Dario
SMSilvia Musio
Silvia Musio
RPRosetta Pedotti
Rosetta Pedotti
Objective: To investigate the potential role of prokineticin 2 (PK2), a bioactive peptide involved in multiple biological functions including immune modulation, in CNS autoimmune demyelinating disease. Methods: We investigated the expression of PK2 in mice with experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), and in patients with relapsing-remitting MS. We evaluated the biological effects of PK2 on expression of EAE and on development of T-cell response against myelin by blocking PK2 in vivo with PK2 receptor antagonists. We treated with PK2 immune cells activated against myelin antigen to explore the immune-modulating effects of this peptide in vitro. Results: Pk2 messenger RNA was upregulated in spinal cord and lymph node cells (LNCs) of mice with EAE. PK2 protein was expressed in EAE inflammatory infiltrates and was increased in sera during EAE. In patients with relapsing-remitting MS, transcripts for PK2 were significantly increased in peripheral blood mononuclear cells compared with healthy controls, and PK2 serum concentrations were significantly higher. A PK2 receptor antagonist prevented or attenuated established EAE in chronic and relapsing-remitting models, reduced CNS inflammation and demyelination, and decreased the production of interferon (IFN)-γ and interleukin (IL)-17A cytokines in LNCs while increasing IL-10. PK2 in vitro increased IFN-γ and IL-17A and reduced IL-10 in splenocytes activated against myelin antigen. Conclusion: These data suggest that PK2 is a critical immune regulator in CNS autoimmune demyelination and may represent a new target for therapy.

15 April 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MCMassimo Costanza
Massimo Costanza
Pietro Luigi PolianiPietro Luigi Poliani
Pietro Luigi Poliani
PPPaola Portararo
Paola Portararo
BCBarbara Cappetti
Barbara Cappetti
SMSilvia Musio
Silvia Musio
SSSabina Sangaletti
Sabina Sangaletti
Significance: A growing body of literature has shown that, aside from carrying genetic information, both nuclear and mitochondrial DNA can be released by innate immune cells and promote inflammatory responses. Here we show that when CD4 + T lymphocytes, key orchestrators of adaptive immunity, are activated, they form a complex extracellular architecture composed of oxidized threads of DNA that provide autocrine costimulatory signals to T cells. We named these DNA extrusions “T helper-released extracellular DNA” (THREDs). We suggest that inhibiting this inflammatory process might represent a new therapeutic modality for CD4 + T cell-mediated autoimmune disorders, such as experimental autoimmune encephalomyelitis, the varied forms of which provide animal models for multiple sclerosis and neuromyelitis optica.

Verified
Journal Article
Open access
PDF file
MCMassimo Costanza
Massimo Costanza
RPRosetta Pedotti
Rosetta Pedotti
The higher prevalence of multiple sclerosis (MS) in females, along with the modulation of disease activity observed during pregnancy and the post-partum period, has suggested a hormonal influence in MS. Even if prolactin (PRL) does not belong to the sex hormones family, its crucial role in female reproduction and lactation has prompted great efforts to understand if PRL could represent a gender factor in the pathogenesis of MS and experimental autoimmune encephalomyelitis (EAE), the animal model for this disease. Extensive literature has documented a remarkable immune-stimulating potential for this hormone, indicating PRL as a disease-promoting factor in MS and EAE. However, recent work has pointed out that PRL is endowed with important neuroprotective and remyelinating properties and has encouraged a reinterpretation of the involvement of this hormone in MS. In this review we summarize both the protective functions that PRL exerts in central nervous system tissue as well as the inflammatory activity of this hormone in the context of autoimmune responses against myelin. Last, we draw future lines of research that might help to better clarify the impact of PRL on MS pathology.

Verified
Journal Article
Open access
PDF file
MCMassimo Costanza
Massimo Costanza
MCMario P. Colombo
Mario P. Colombo
RPRosetta Pedotti
Rosetta Pedotti
Mast cells (MCs) are best known as key immune players in immunoglobulin E (IgE)-dependent allergic reactions. In recent years, several lines of evidence have suggested that MCs might play an important role in several pathological conditions, including autoimmune disorders such as multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), an animal model for MS. Since their first description in MS plaques in the late 1800s, much effort has been put into elucidating the contribution of MCs to the development of central nervous system (CNS) autoimmunity. Mouse models of MC-deficiency have provided a valuable experimental tool for dissecting MC involvement in MS and EAE. However, to date there is still major controversy concerning the function of MCs in these diseases. Indeed, although MCs have been classically proposed as having a detrimental and pro-inflammatory role, recent literature has questioned and resized the contribution of MCs to the pathology of MS and EAE. In this review, we will present the main evidence obtained in MS and EAE on this topic, and discuss the critical and controversial aspects of such evidence.